R. Angermund

Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.

J. Debus, P. Drings, W. Baurecht, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

M. Beksac, M. Dimopoulos, T. Facon, 2013, Haematologica.

The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM).

R. Angermund, M. Schroeder, G. Thompson, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial.

U. Reinhardt, R. Angermund, A. Tulusan, 2005, The oncologist.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

A. Jauch, T. Hielscher, M. Görner, 2017, Bone Marrow Transplantation.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

M. Dimopoulos, J. Drach, J. Bladé, 2013, British journal of haematology.

Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO® Registry

C. Bokemeyer, W. Freier, F. Honecker, 2021, Journal of Cancer Research and Clinical Oncology.

Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study

A. Oriol, I. Kotsianidis, R. Olie, 2015, Hematology.

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

H. Goldschmidt, T. Hielscher, M. Vogel, 2017 .